Summary

The clinical trial services market is projected to reach USD 97.41 billion by 2031 from USD 66.20 billion in 2026, at a CAGR of 8.0% during the forecast period of 2026 to 2031. The expanding pipeline of cell & gene therapies (CGTs) and precision medicines is increasing demand for specialized outsourced Phase I–IV clinical trial services. These programs often involve complex protocols, biomarker- or genomic-based patient selection, small and geographically dispersed patient populations, specialized site requirements, stringent sample handling, customized clinical supply and logistics, and extended safety follow-up. Such requirements are encouraging sponsors to engage CROs and specialized providers with capabilities in site identification and management, patient recruitment, clinical monitoring, laboratory and biomarker testing, data management, pharmacovigilance, and clinical trial logistics.

By service type, the laboratory services segment accounted for the second-largest share of the clinical trial services market in 2025.
By service type, the clinical trial services market is segmented into laboratory services, site management and monitoring, site contracts and payments, patient recruitment and retention, medical writing, clinical trial supply & logistics services, safety and pharmacovigilance, clinical trial data management services, consulting, and other clinical trial services. In 2025, laboratory services accounted for the second-largest share of the market, following site management and monitoring. The significant share of laboratory services stems from the extensive need for analytical and bioanalytical testing during Phase I–IV clinical trials to measure drug concentrations, evaluate pharmacokinetics, assess biomarkers and immunogenicity, and generate reliable laboratory data for efficacy and safety assessments. Increasing development of biologics, oncology therapies, cell & gene therapies, and other complex modalities is further increasing demand for specialized assays, biomarker testing, and high-quality bioanalytical capabilities, encouraging sponsors to outsource these activities to CROs and specialized laboratories.

By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the clinical trial services market in 2025.
Based on end user/sponsor, the clinical trial services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Pharmaceutical & biopharmaceutical companies are further segmented into large and mid-size and small companies. In 2025, pharmaceutical & biopharmaceutical companies accounted for the largest market share. This segment's large share is driven by extensive Phase I–IV clinical development pipelines, substantial R&D expenditure, increasing protocol complexity, and growing reliance on CROs for global trial execution. Outsourcing enables these sponsors to access specialized therapeutic expertise, global site and patient networks, scalable clinical operations resources, and capabilities in site management and monitoring, laboratory testing, data management, pharmacovigilance, patient recruitment, and clinical trial logistics while improving operational flexibility and development efficiency.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the global clinical trial services market, supported by a well-established pharmaceutical and biopharmaceutical industry, high R&D expenditure, and substantial demand for outsourced Phase I–IV clinical trial services. The region also benefits from a dense network of clinical research sites, hospitals, academic medical centers, and specialized laboratories, providing strong infrastructure for large-scale and complex clinical studies. In addition, the rapid adoption of decentralized and hybrid trial models, digital patient-engagement tools, risk-based monitoring, and advanced clinical data technologies, particularly in the US, is further supporting demand for services such as site management and monitoring, patient recruitment and retention, data management, pharmacovigilance, laboratory testing, and clinical trial logistics. These factors continue to strengthen North America’s position as the leading regional market for outsourced clinical trial services.
・List of Companies Profiled in the Report:
・IQVIA Inc. (US)
・Thermo Fisher Scientific Inc. (US)
・Fortrea (US)
・ICON Plc (Ireland)
・Syneos Health (US)
・Laboratory Corporation of America Holdings (US)
・Medpace (US)
・Wuxi AppTec (China)
・Frontage Labs (US)
・Pharmaron (US)
・Tigermed (China)
・SGS Société Générale de Surveillance SA. (Switzerland)
・Eurofins Scientific (Luxembourg)
・Linical (Japan)
・Parexel International Corporation (US)
・Worldwide Clinical Trials (US)
・Novotech (Australia)
・PSI (Switzerland)
・Allucent (US)
・Premier Research (US)
・Clario (US)
・KCR S.A. (US)
・Rho, Inc. (US)
・Advanced Clinical (US)

Research Coverage
This research report categorizes the clinical trial services market by service type, phase, therapeutic area, modality, delivery model, study design, end user/sponsor, and region.
The report provides detailed information on the key drivers, opportunities, and challenges influencing the growth of the clinical trial services market, including increasing pipeline and trial complexity, growing R&D investment, service flexibility offered by CROs, demand for faster drug-development timelines, evolving outsourcing models, regulatory modernization, AI and data analytics, decentralized and patient/site-centric trials, patient recruitment and retention challenges, and shortages of specialized clinical research talent. It also analyzes industry trends, technology developments, regulatory and sustainability considerations, customer landscape, pricing, ecosystem dynamics, and the competitive landscape. A detailed assessment of key market participants covers their service portfolios, strategies, market positioning, partnerships, agreements, and other strategic developments, including service launches, deals, collaborations, partnerships, and acquisitions associated with the clinical trial services market.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall clinical trial services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will help stakeholders understand the market's pulse and provide information on key market drivers, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (growing pipeline complexity and increasing clinical-trial activity in specialty therapies, growing R&D investments and presence of a robust clinical pipeline, service flexibility offered by CROs, demand for faster drug-development timelines and productivity improvement, and the gradual shift from full-service CRO toward FSP/hybrid/strategic outsourcing models), opportunities (regulatory modernization and innovative trial designs, AI, automation and data analytics in clinical development, and patient/site-centric and decentralized clinical trials), and challenges (patient recruitment and retention and shortage of qualified clinical research talent and specialized expertise) influencing the growth of the clinical trial services market
・Service Development/Innovation: Detailed insights into newly introduced and evolving clinical trial services and technology-enabled solutions
・Market Development: Comprehensive information about lucrative markets—the report analyzes the market across varied regions.
・Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
・Competitive Assessment: In-depth assessment of market shares, growth strategies, service offerings, and competitive positioning of key clinical trial service providers, including Thermo Fisher Scientific Inc. (PPD, Inc.), IQVIA Inc., ICON plc, Laboratory Corporation of America Holdings, Syneos Health, WuXi AppTec, Eurofins Scientific, Parexel International Corporation, Fortrea Inc., Medpace, SGS, Frontage Labs, Pharmaron, Tigermed, and BioAgile, among others. The report analyzes key strategies, service launches, deals, acquisitions, partnerships, agreements, collaborations, expansions, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics in the clinical trial services market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 55
1.1 STUDY OBJECTIVES 55
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 56
1.3 MARKET SCOPE 58
1.3.1 MARKETS COVERED 58
1.3.2 REGIONAL SCOPE 59
1.3.3 YEARS CONSIDERED 59
1.4 CURRENCY 59
1.5 STAKEHOLDERS 60
1.6 SUMMARY OF CHANGES 60
2 EXECUTIVE SUMMARY 62
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 62
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 64
2.3 DISRUPTIVE TRENDS SHAPING MARKET 65
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 66
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 67
3 PREMIUM INSIGHTS 69
3.1 GLOBAL CLINICAL TRIAL SERVICES MARKET SNAPSHOT 69
3.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY, 2025 70
3.3 CLINICAL TRIAL SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 73
4.2.1.1 Growing pipeline complexity and increasing clinical-trial activity in specialty and advanced therapies 73
4.2.1.2 Resilient biopharma R&D investment and broad clinical-development pipeline 74
4.2.1.3 Flexible and scalable service delivery offered by CROs 75
4.2.1.4 Pressure to shorten development timelines and improve clinical R&D productivity 75
4.2.1.5 Growing adoption of FSP, hybrid, and strategic portfolio-based outsourcing models 76
4.2.2 OPPORTUNITIES 76
4.2.2.1 Regulatory modernization and adoption of innovative trial designs 76
4.2.2.2 AI, automation, and advanced data analytics across clinical development 76
4.2.2.3 Patient- and site-centric, decentralized, and hybrid clinical-trial models 77
4.2.3 CHALLENGES 77
4.2.3.1 Patient recruitment, enrollment, and retention constraints 77
4.2.3.2 Shortage of qualified clinical-research talent and specialized domain expertise 77
4.3 UNMET NEEDS AND WHITE SPACES 78
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 78
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 79
5 INDUSTRY TRENDS 80
5.1 MARKET TRENDS 80
5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN 80
5.1.2 INCREASING FOCUS ON IN SILICO TRIALS 80
5.1.3 FSP AND HYBRID OUTSOURCING ARE GAINING STRATEGIC IMPORTANCE VERSUS ONE-SIZE-FITS-ALL FULL-SERVICE OUTSOURCING 81
5.1.4 SUSTAINABILITY AND ESG PRESSURES ARE SHAPING CLINICAL TRIALS 81
5.1.5 SUPPLIER CONSOLIDATION AND STRATEGIC PARTNERSHIPS REDEFINE MARKET 81
5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
5.3 PRICING ANALYSIS 82
5.3.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 82
5.3.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025 83
5.3.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 84
5.4 VALUE CHAIN ANALYSIS 85
5.5 ECOSYSTEM ANALYSIS 87
5.6 INVESTMENT/FUNDING ACTIVITY 88
5.7 KEY CONFERENCES & EVENTS 89
5.8 PORTER’S FIVE FORCES ANALYSIS 90
5.8.1 THREAT OF NEW ENTRANTS 91
5.8.2 THREAT OF SUBSTITUTES 91
5.8.3 BARGAINING POWER OF BUYERS 91
5.8.4 BARGAINING POWER OF SUPPLIERS 91
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 92
5.9 IMPACT OF 2025 TRUMP TARIFF ON CLINICAL TRIAL SERVICES MARKET 92
5.9.1 INTRODUCTION 92
5.9.2 KEY TARIFF RATES 92
5.9.3 PRICE IMPACT ANALYSIS 92
5.9.4 IMPACT ON COUNTRY/REGION 93
5.9.4.1 North America 93
5.9.4.1.1 US 93
5.9.4.2 Europe 93
5.9.4.3 Asia Pacific 94
5.9.5 IMPACT ON END-USE INDUSTRIES 94
5.9.5.1 Pharmaceutical & biotech companies 94
5.9.5.2 Medical devices companies 94
5.9.5.3 Academic institutes 95
5.10 MACROECONOMIC OUTLOOK 95
5.10.1 INTRODUCTION 95
5.10.2 GDP TRENDS AND FORECAST 95
5.10.3 TRENDS IN GLOBAL CLINICAL TRIAL SERVICES MARKET 96
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE N IMPACT, INNOVATIONS AND FUTURE APPLICATIONS 97
6.1 TECHNOLOGY ANALYSIS 97
6.1.1 KEY TECHNOLOGIES 97
6.1.1.1 AI-integrated Clinical Trial Management System (CTMS) & Electronic Trial Master File (eTMF) platforms 97
6.1.1.2 Randomization and Trial Supply Management (RTSM) 97
6.1.1.3 Electronic Data Capture (EDC) System 98
6.1.2 COMPLEMENTARY TECHNOLOGIES 99
6.1.2.1 Digital Biomarkers, Wearables & Electronic Patient-Reported Outcome (EPRO) Tools 99
6.1.2.2 Model-Informed Drug Development (MIDD) 99
6.1.2.3 Data Management and Informatics Technologies 99
6.1.2.4 Real-world evidence (RWE) & real-world data (RWD) platforms 100
6.1.3 ADJACENT TECHNOLOGY 100
6.1.3.1 Clinical trial simulation tools 100
6.2 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 101
6.2.1 INTRODUCTION 101
6.2.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES 101
6.2.3 KEY COMPANIES IMPLEMENTING AI 103
6.2.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM 103
6.3 TECHNOLOGY/SERVICE ROADMAP 103
6.4 FUTURE APPLICATIONS 103
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.2 REGULATORY FRAMEWORK & CLINICAL TRIAL AUTHORIZATION 108
7.1.3 INDUSTRY STANDARDS 110
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 111
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 112
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 KEY STAKEHOLDERS AND BUYING CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 BUYING CRITERIA 114
8.3 CUSTOMER LANDSCAPE 116
8.3.1 BUDGET ALLOCATION TREND 116
8.3.2 ADOPTION BARRIER & INTERNAL CHALLENGES 116
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 117
8.5 MARKET PROFITABILITY 117
9 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE 118
9.1 INTRODUCTION 119
9.2 CLINICAL TRIAL MANAGEMENT & MONITORING 120
9.2.1 ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH 120
9.3 LABORATORY SERVICES 124
9.3.1 ANALYTICAL TESTING SERVICES 128
9.3.1.1 Increasing demand for analytical testing for drug development to drive market 128
9.3.2 BIOANALYTICAL TESTING SERVICES 131
9.3.2.1 Rising focus on biologics in advanced therapies to drive market 131
9.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES 135
9.4.1 GROWING RELIANCE ON DATA FOR CLINICAL EVALUATIONS BY REGULATORY BODIES TO SUPPORT MARKET GROWTH 135
9.4.2 BIOSTATISTICS 140
9.4.2.1 Integration of real-world data (RWD) into statistical analysis to support market growth 140
9.4.3 OTHER DATA MANAGEMENT SERVICES 143
9.5 CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES 146
9.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET 146
9.6 CONSULTING 150
9.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET 150
9.7 PATIENT RECRUITMENT & RETENTION 153
9.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH 153
9.8 MEDICAL WRITING 156
9.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET 156
9.9 SAFETY & PHARMACOVIGILANCE 159
9.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH 159
9.10 SITE CONTRACTS & PAYMENTS 163
9.10.1 GROWING NEED FOR STREAMLINED SITE CONTRACTING AND PAYMENT MANAGEMENT TO SUPPORT MARKET GROWTH 163
9.11 OTHER SERVICE TYPES 166
10 CLINICAL TRIAL SERVICES MARKET, BY PHASE 170
10.1 INTRODUCTION 171
10.2 PHASE III 172
10.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING 172
10.3 PHASE II 175
10.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS 175
10.4 PHASE I 179
10.4.1 DECLINING TRIALS TO POSE GROWTH CHALLENGE TO MARKET 179
10.5 PHASE IV 182
10.5.1 SIGNIFICANCE OF PHASE IV TO SUPPORT MARKET GROWTH 182
11 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL 185
11.1 INTRODUCTION 186
11.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 186
11.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 186
11.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 189
11.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 189
11.4 HYBRID MODEL 192
11.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH 192
12 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN 195
12.1 INTRODUCTION 196
12.2 INTERVENTIONAL 196
12.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET 196
12.3 OBSERVATIONAL 200
12.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH 200
13 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 204
13.1 INTRODUCTION 205
13.2 ONCOLOGY 206
13.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET 206
13.2.2 BREAST CANCER 211
13.2.2.1 Increasing cases and high spending on treating breast cancer to support growth 211
13.2.3 LUNG CANCER 215
13.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth 215
13.2.4 COLORECTAL CANCER 218
13.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth 218
13.2.5 PROSTATE CANCER 222
13.2.5.1 Growing clinical pipeline to propel market 222
13.2.6 OTHER CANCER 225
13.3 NEUROLOGY 228
13.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET 228
13.4 RESPIRATORY DISORDERS 232
13.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 232
13.5 METABOLIC DISORDERS/ENDOCRINOLOGY 236
13.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH 236
13.6 CARDIOVASCULAR SYSTEM DISORDERS 240
13.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET 240
13.7 DERMATOLOGY 243
13.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR DIFFERENT SKIN CONDITIONS TO SUPPORT MARKET GROWTH 243
13.8 GASTROINTESTINAL DISEASES 247
13.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET 247
13.9 IMMUNOLOGICAL DISORDERS 250
13.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH 250
13.10 INFECTIOUS DISEASES 254
13.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET 254
13.11 PSYCHIATRY 257
13.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH 257
13.12 OPHTHALMOLOGY 261
13.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH 261
13.13 HEMATOLOGY 265
13.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 265
13.14 GENITOURINARY & WOMEN’S HEALTH 268
13.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET 268
13.15 OTHER THERAPEUTIC AREAS 272
14 CLINICAL TRIAL SERVICES MARKET, BY MODALITY 276
14.1 INTRODUCTION 277
14.2 SMALL MOLECULES 277
14.2.1 STRONG PIPELINE GROWTH AND GROWING INVESTMENTS TO SUPPORT GROWTH 277
14.3 BIOLOGICS 280
14.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND REGULATORY SUPPORT TO PROPEL DEMAND 280
14.4 MONOCLONAL ANTIBODY 283
14.4.1 SURGING DEMAND FOR TARGETED THERAPIES TO DRIVE MARKET 283
14.5 CELL & GENE THERAPY 286
14.5.1 DEVELOPMENT COMPLEXITY AND REGULATORY MOMENTUM TO DRIVE CRO DEMAND 286
14.6 OTHER BIOLOGICS 289
14.7 BIOSIMILARS 292
14.7.1 INCREASING DEMAND FOR COST-EFFECTIVE ALTERNATIVES TO SUPPORT BIOSIMILARS GROWTH, THUS AIDING OUTSOURCING 292
14.8 MEDICAL DEVICES & IVD 294
14.8.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND 294
15 CLINICAL TRIAL SERVICES MARKET, BY END USER 298
15.1 INTRODUCTION 299
15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 299
15.2.1 INCREASE IN R&D EXPENDITURE OF PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 299
15.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 303
15.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs 303
15.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 306
15.2.3.1 Demand driven by limited internal capabilities and rising trial complexity 306
15.3 MEDICAL DEVICE COMPANIES 309
15.3.1 RISING REGULATORY EVIDENCE REQUIREMENTS AND EXPANSION OF INTEGRATED SERVICE PORTFOLIOS BY MEDTECH CROS TO DRIVE MARKET GROWTH 309
15.4 ACADEMIC INSTITUTES 313
15.4.1 EXPANDING CRO–ACADEMIC PARTNERSHIPS AND SITE NETWORKS TO DRIVE MARKET 313
16 CLINICAL TRIAL SERVICES MARKET, BY REGION 317
16.1 INTRODUCTION 318
16.2 NORTH AMERICA 318
16.2.1 US 325
16.2.1.1 Presence of well-established CROs to drive market 325
16.2.2 CANADA 331
16.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market 331
16.3 EUROPE 337
16.3.1 GERMANY 343
16.3.1.1 Growing R&D spending and favorable government policies to propel market 343
16.3.2 UK 349
16.3.2.1 Rising collaborations and improved policies to support market 349
16.3.3 FRANCE 355
16.3.3.1 Government-led support for effective drug research to drive market 355
16.3.4 ITALY 361
16.3.4.1 Government-led focus on improving clinical trial regulations to drive market 361
16.3.5 SPAIN 366
16.3.5.1 Rising R&D expenditure to boost market growth 366
16.3.6 REST OF EUROPE 371
16.4 ASIA PACIFIC 377
16.4.1 CHINA 383
16.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market 383
16.4.2 INDIA 389
16.4.2.1 Cost-efficient and innovation-driven approach to propel market 389
16.4.3 JAPAN 395
16.4.3.1 Slight decline in number of clinical trials to limit market 395
16.4.4 AUSTRALIA 400
16.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market 400
16.4.5 SOUTH KOREA 405
16.4.5.1 Favorable government initiatives for drug development to drive market 405
16.4.6 REST OF ASIA PACIFIC 411
16.5 LATIN AMERICA 416
16.5.1 BRAZIL 421
16.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market 421
16.5.2 MEXICO 427
16.5.2.1 Increasing investments in pharma R&D to drive market 427
16.5.3 REST OF LATIN AMERICA 432
16.6 MIDDLE EAST 437
16.6.1 GCC COUNTRIES 442
16.6.1.1 Saudi Arabia 447
16.6.1.1.1 Increase in collaborations to drive market 447
16.6.1.2 UAE 452
16.6.1.2.1 Growing clinical research activities to drive market 452
16.6.1.3 Rest of GCC Countries 457
16.6.2 REST OF MIDDLE EAST 462
16.6.3 AFRICA 467
16.6.3.1 Expanding pharmaceutical industry to support market growth 467
17 COMPETITIVE LANDSCAPE 472
17.1 OVERVIEW 472
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2025 472
17.3 REVENUE ANALYSIS, 2023–2025 475
17.3.1 CLINICAL TRIAL SERVICES MARKET 475
17.4 MARKET SHARE ANALYSIS, 2025 476
17.4.1 CLINICAL TRIAL SERVICES MARKET 476
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 479
17.5.1 CLINICAL TRIAL SERVICES MARKET 479
17.5.2 STARS 479
17.5.3 EMERGING LEADERS 479
17.5.4 PERVASIVE PLAYERS 479
17.5.5 PARTICIPANTS 479
17.5.5.1 Company footprint: Key players, 2025 481
17.5.5.1.1 Company footprint 481
17.5.5.2 Region footprint 482
17.5.5.3 Service type footprint 483
17.5.5.4 Phase footprint 484
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 485
17.6.1 CLINICAL TRIAL SERVICES MARKET: STARTUPS/SMES, 2025 485
17.6.2 PROGRESSIVE COMPANIES 485
17.6.3 RESPONSIVE COMPANIES 485
17.6.4 DYNAMIC COMPANIES 485
17.6.5 STARTING BLOCKS 485
17.6.5.1 Competitive benchmarking 487
17.6.5.1.1 Detailed list of key startups/SMES 487
17.6.5.1.2 Competitive benchmarking of startups/SMEs 488
17.7 COMPANY VALUATION AND FINANCIAL METRICS 489
17.7.1 CLINICAL TRIAL SERVICES MARKET 489
17.8 BRAND/SERVICE COMPARISON 490
17.9 COMPETITIVE SCENARIO 491
17.9.1 SERVICE LAUNCHES 491
17.9.2 DEALS 492
17.9.3 EXPANSIONS 493
18 COMPANY PROFILES 494
18.1 KEY PLAYERS 494
18.1.1 IQVIA INC. 494
18.1.1.1 Business overview 494
18.1.1.2 Solutions/Services offered 495
18.1.1.3 Recent developments 497
18.1.1.3.1 Service/Solution launches 497
18.1.1.3.2 Deals 498
18.1.1.4 MnM view 499
18.1.1.4.1 Right to win 499
18.1.1.4.2 Strategic choices 500
18.1.1.4.3 Weaknesses and competitive threats 500
18.1.2 ICON PLC 501
18.1.2.1 Business overview 501
18.1.2.2 Services/Solutions offered 502
18.1.2.3 Recent developments 504
18.1.2.3.1 Service launches 504
18.1.2.3.2 Deals 505
18.1.2.3.3 Expansions 506
18.1.2.4 MnM view 506
18.1.2.4.1 Right to win 506
18.1.2.4.2 Strategic choices 506
18.1.2.4.3 Weaknesses and competitive threats 506
18.1.3 THERMO FISHER SCIENTIFIC INC. 507
18.1.3.1 Business overview 507
18.1.3.2 Services/Solutions offered 508
18.1.3.3 Recent developments 511
18.1.3.3.1 Product/Service launches 511
18.1.3.3.2 Deals 512
18.1.3.3.3 Expansions 513
18.1.3.4 MnM view 513
18.1.3.4.1 Right to win 513
18.1.3.4.2 Strategic choices 514
18.1.3.4.3 Weaknesses and competitive threats 514
18.1.4 FORTREA 515
18.1.4.1 Business overview 515
18.1.4.2 Services/Solutions offered 516
18.1.4.3 Recent developments 519
18.1.4.3.1 Service launches 519
18.1.4.3.2 Deals 520
18.1.4.3.3 Expansions 520
18.1.4.3.4 Other developments 520
18.1.4.4 MnM view 521
18.1.4.4.1 Right to win 521
18.1.4.4.2 Strategic choices 521
18.1.4.4.3 Weaknesses and competitive threats 521
18.1.5 SYNEOS HEALTH 522
18.1.5.1 Business overview 522
18.1.5.2 Services/Solutions offered 523
18.1.5.3 Recent developments 524
18.1.5.3.1 Service launches 524
18.1.5.3.2 Deals 525
18.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 526
18.1.6.1 Business overview 526
18.1.6.2 Services/Solutions offered 527
18.1.6.3 Recent developments 528
18.1.6.3.1 Service/ Solution launches 528
18.1.6.3.2 Deals 529
18.1.6.3.3 Expansions 530
18.1.6.4 MnM view 530
18.1.6.4.1 Right to win 530
18.1.6.4.2 Strategic choices 530
18.1.6.4.3 Weaknesses and competitive threats 530
18.1.7 MEDPACE 531
18.1.7.1 Business overview 531
18.1.7.2 Services/Solutions offered 532
18.1.8 WUXI APPTEC 534
18.1.8.1 Business overview 534
18.1.8.2 Services/Solutions offered 535
18.1.8.3 Recent developments 537
18.1.8.3.1 Deals 537
18.1.8.3.2 Expansions 537
18.1.8.4 Other developments 537
18.1.9 FRONTAGE LABS 538
18.1.9.1 Business overview 538
18.1.9.2 Services/Solutions offered 539
18.1.9.3 Recent developments 540
18.1.9.3.1 Deals 540
18.1.10 PHARMARON 541
18.1.10.1 Business overview 541
18.1.10.2 Services/Solutions offered 543
18.1.11 TIGERMED 544
18.1.11.1 Business overview 544
18.1.11.2 Services offered 545
18.1.11.3 Recent developments 547
18.1.11.3.1 Service approvals 547
18.1.11.3.2 Deals 548
18.1.12 SGS SA 549
18.1.12.1 Business overview 549
18.1.12.2 Services/Solutions offered 550
18.1.12.3 Recent developments 552
18.1.12.3.1 Deals 552
18.1.12.3.2 Expansions 552
18.1.13 EUROFINS SCIENTIFIC 553
18.1.13.1 Business overview 553
18.1.13.2 Services/Solutions offered 554
18.1.14 LINICAL 556
18.1.14.1 Business overview 556
18.1.14.2 Services/Solutions offered 557
18.1.14.3 Recent developments 558
18.1.14.4 Expansions 558
18.1.15 PAREXEL INTERNATIONAL CORPORATION 559
18.1.15.1 Business overview 559
18.1.15.2 Services/Solutions offered 559
18.1.15.3 Recent developments 561
18.1.15.3.1 Product & service launches 561
18.1.15.3.2 Deals 561
18.1.15.3.3 Expansions 562
18.1.16 PSI CRO AG 563
18.1.16.1 Business overview 563
18.1.16.2 Services/Solutions offered 563
18.1.16.3 Recent developments 564
18.1.16.3.1 Service launches 564
18.1.16.3.2 Deals 564
18.1.16.3.3 Expansions 565
18.1.17 NOVOTECH 566
18.1.17.1 Business overview 566
18.1.17.2 Services/Solutions offered 566
18.1.17.3 Recent developments 569
18.1.17.3.1 Deals 569
18.1.18 BIOAGILE 570
18.1.18.1 Business overview 570
18.1.18.2 Services/Solutions offered 570
18.1.19 ADVANCED CLINICAL 572
18.1.19.1 Business overview 572
18.1.19.2 Services/Solutions offered 572
18.1.19.3 Recent developments 573
18.1.19.3.1 Deals 573
18.1.20 FIRMA CLINICAL RESEARCH 574
18.1.20.1 Business overview 574
18.1.20.2 Services/Solutions offered 574
18.2 OTHER PLAYERS 575
18.2.1 WORLDWIDE CLINICAL TRIALS 575
18.2.2 PROPHARMA 576
18.2.3 ALLUCENT 578
18.2.4 PREMIER RESEARCH 579
18.2.5 CAIDYA 580
18.2.6 ERGOMED GROUP 581
18.2.7 CLARIO 583
18.2.8 PRECISION MEDICINE GROUP, LLC. 584
18.2.9 EPS HOLDINGS, INC. 585
18.2.10 GUIRES INC. (PEPGRA) 586
18.2.11 KCR S.A. 587
19 RESEARCH METHODOLOGY 588
19.1 RESEARCH APPROACH 588
19.1.1 SECONDARY DATA 589
19.1.1.1 Key sources of secondary data 589
19.1.1.2 Key objectives of secondary research 589
19.1.2 PRIMARY DATA 590
19.1.2.1 Breakdown of primaries 590
19.1.2.2 Key objectives of primary research 590
19.2 MARKET ESTIMATION METHODOLOGY 591
19.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 591
19.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH 593
19.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 594
19.3 GROWTH RATE PROJECTIONS 595
19.4 DATA TRIANGULATION 597
19.5 RESEARCH ASSUMPTIONS 598
19.6 RESEARCH LIMITATIONS 599
19.7 RISK ANALYSIS 599
20 APPENDIX 600
20.1 DISCUSSION GUIDE 600
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 605
20.3 CUSTOMIZATION OPTIONS 607
20.4 RELATED REPORTS 607
20.5 AUTHOR DETAILS 608